3 research outputs found
Winter Cholecalciferol Supplementation at 55°N Has No Effect on Markers of Cardiometabolic Risk in Healthy Children Aged 4–8 Years
No full textBackground: Low serum 25-hydroxyvitamin D [25(OH)D] has been associated with unfavorable cardiometabolic risk
profiles in many observational studies in children, but very few randomized controlled trials have investigated this.
Objective: We explored the effect of winter-time cholecalciferol (vitamin D3) supplementation on cardiometabolic risk
markers in young, white, 4- to 8-y-old healthy Danish children (55°N) as part of the pan-European ODIN project.
Methods: In the ODIN Junior double-blind, placebo-controlled, dose-response trial, 119 children (mean ± SD age:
6.7 ± 1.5 y; 36% male; 82% normal weight) were randomly allocated to 0, 10 or 20 μg/d of vitamin D3 for 20 wk
(October–March). Cardiometabolic risk markers including BMI-for-age z score (BMIz), waist circumference, systolic and
diastolic blood pressure, serum triglycerides and cholesterol (total, LDL, HDL, and total:HDL), plasma glucose and insulin,
and whole-blood glycated hemoglobin were measured at baseline and endpoint as secondary outcomes together
with serum 25(OH)D. Intervention effects were evaluated in linear regression models as between-group differences at
endpoint adjusted for baseline value of the outcome, and additionally for age, sex, baseline serum 25(OH)D, BMIz, time
since breakfast, and breakfast content.
Results: Mean ± SD serum 25(OH)D was 56.7 ± 12.3 nmol/L at baseline and differed between groups at endpoint
with concentrations of 31.1 ± 7.5, 61.8 ± 10.6, and 75.8 ± 11.5 nmol/L in the 0-, 10-, and 20 μg/d groups, respectively
(P < 0.0001). Vitamin D3 supplementation had no effect on any of the cardiometabolic risk markers in analyses adjusted
for baseline value of the outcome (all P ≥ 0.05), and additional covariate adjustment did not change the results notably.
Conclusions: Preventing the winter decline in serum 25(OH)D with daily vitamin D3 supplementation of 10 or 20 ÎĽg had
no cardiometabolic effects in healthy 4- to 8-y-old Danish children. This trial was registered at www.clinicaltrials.gov as
NCT02145195
